Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks

Merck & Co. Inc. (NYSE: MRK ) keeps on generating more and more revenue, with revenue guidance for FY 2024 up 6-7% from 2023. Much of the added revenue, and more than the entire revenue of the company, is generated by Keytruda, the company's oncology product. Although I am a long-term investor focused on growth markets, AI and biotech opportunities in my more volatile portfolio. I try to look for undervalued and under-the-radar stocks with serious potential and good scientific or other background. My ambiti ...